COVID-19 still killing 300 Americans weekly in 2025: Low vaccine uptake blamed

Why Are Hundreds of Americans Still Dying from COVID-19 Each Week in 2025?

Despite broad access to vaccines and antiviral therapies, the United States continues to report more than 300 COVID-19 deaths each week. This stubbornly persistent mortality rate has puzzled many observers who assumed the pandemic’s worst had passed. But public health experts point to a constellation of contributing factors—ranging from vaccine fatigue and policy restrictions to low uptake of treatment options and the emergence of new viral variants—as key reasons behind the lingering toll.

What Is the Current State of COVID-19 Fatalities in the U.S.?

As of mid-2025, the Centers for Disease Control and Prevention (CDC) continues to log over 300 COVID-19-related deaths weekly across the U.S., a figure that has remained relatively stable for months. While far below the peak levels seen in 2020 and 2021, this rate translates to more than 15,000 deaths annually—making COVID-19 one of the leading causes of infectious disease-related mortality in the country. The persistence of these numbers has underscored growing concerns that for vulnerable populations, the pandemic is far from over.

Epidemiologists emphasize that these deaths are largely concentrated among older adults, the immunocompromised, and those with underlying conditions. However, preventable fatalities are occurring due to missed vaccination boosters, limited therapeutic access, and systemic public health fatigue.

Why Is U.S. COVID-19 Vaccine Uptake So Low in 2025?

A major contributor to the ongoing death toll is low uptake of updated COVID-19 vaccines. According to CDC data, only around 20% of American adults have received the most recent COVID-19 booster, which was reformulated and made available in September 2024. Among seniors—who represent the majority of COVID-19 deaths—booster coverage hovers just above 40%, leaving millions at elevated risk.

Public health experts point to “vaccine fatigue” and a declining sense of urgency among the public. With no federal mandates in place and widespread pandemic disillusionment, the social and political momentum that once fueled vaccination campaigns has weakened. Misinformation on social media, politicized discourse, and a lack of proactive reminders from healthcare providers have all exacerbated hesitancy.

To complicate matters, a recent policy shift by the Food and Drug Administration (FDA) has narrowed vaccine eligibility for upcoming seasons. Beginning fall 2025, the U.S. COVID-19 vaccination strategy will prioritize only high-risk populations, such as seniors and those with specific medical vulnerabilities. While intended to optimize resource allocation, experts warn this may further reduce public perception of vaccine importance and suppress uptake across the general population.

Are COVID-19 Treatments Being Widely Used?

Despite the availability of effective treatments like Paxlovid, timely access remains a challenge. Health systems across the U.S. have struggled with equitable distribution, particularly in rural or underserved urban areas. Many patients, especially those without a primary care provider or with limited insurance coverage, miss the critical early window for antiviral treatment.

Moreover, public awareness about treatment options remains low. Surveys conducted in early 2025 revealed that nearly half of Americans over the age of 60 were unaware that they qualified for Paxlovid or similar therapies. Even among those who knew, many reported difficulty in obtaining prescriptions quickly enough to meet the five-day treatment window post-symptom onset.

Healthcare providers have also expressed frustration with shifting guidance and logistical hurdles, from navigating electronic health record systems to pharmacy supply shortages. These frictions reduce the likelihood that high-risk patients will receive timely interventions that could prevent hospitalization or death.

How Do New COVID Variants Influence Death Rates?

While the original virus has mutated extensively since 2020, new variants continue to circulate in 2025. The NB.1.8.1 subvariant, identified in early 2025, has drawn particular attention for its high transmissibility. Although vaccines remain effective at reducing severe outcomes, each mutation slightly alters the virus’s spike protein, allowing partial immune evasion. For those unvaccinated or overdue for a booster, these subvariants represent a renewed threat.

Virologists note that while new variants may not be inherently more lethal, the risk profile increases in populations with waning immunity. Reinfection, while often mild, can lead to complications in older or vulnerable individuals. Hospital systems have also reported a rise in long COVID symptoms and complications following reinfections, further underscoring the virus’s evolving threat.

What Role Does Public Policy and Health Infrastructure Play?

The U.S. public health response in 2025 reflects a marked shift from the aggressive mitigation strategies of earlier years. Many states have scaled back COVID surveillance, testing programs, and contact tracing. Funding for emergency outreach, vaccination pop-ups, and telehealth support has declined.

At the federal level, the transition away from the public health emergency designation in 2023 led to a rollback in centralized response coordination. Without national mandates or funding incentives, much of the burden has fallen on overstretched state and local health departments.

Compounding these systemic gaps is a broader cultural shift. With mask mandates and distancing measures largely a thing of the past, COVID-19 is increasingly viewed as a manageable seasonal illness akin to the flu. But unlike influenza, which has built-in annual vaccination infrastructure and decades of public familiarity, COVID-19 continues to encounter resistance in policy, practice, and public consciousness.

How Does This Impact the Most Vulnerable Populations?

The enduring weekly death toll disproportionately affects older Americans, particularly those in long-term care facilities. Immunocompromised individuals and communities of color—many of whom face structural healthcare barriers—also bear the brunt of preventable outcomes.

Data from the Department of Health and Human Services (HHS) suggests that in states with lower vaccination rates and limited health infrastructure, COVID-19 mortality remains significantly above the national average. Southern and Midwestern states continue to report higher per capita death rates, highlighting geographic disparities in healthcare access and public health execution.

Experts stress that without a reinvigorated national effort—focusing on vaccine outreach, treatment education, and tailored messaging for high-risk communities—these inequalities will persist. “We are watching preventable deaths in slow motion,” noted one epidemiologist from a major university’s public health school, adding that the tools exist, but the urgency has faded.

Is There a Path Forward?

While the current weekly death rate remains concerning, experts believe it is possible to reduce this burden significantly. Key strategies include improving booster uptake among seniors, streamlining antiviral access, restoring community-based outreach efforts, and reestablishing trust through transparent, science-based communication.

Emerging research on next-generation vaccines, including universal coronavirus platforms and nasal sprays, could offer improved protection and ease of administration. In parallel, simplifying the prescription process for treatments like Paxlovid could ensure more timely interventions for at-risk individuals.

Ultimately, experts agree that while society may have moved past the acute crisis phase of COVID-19, the virus has not vanished—and neither should the response.